ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 1544 • 2014 ACR/ARHP Annual Meeting

    Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients Comorbid with Psoriatic Arthritis

    Steven R Feldman1, Yang Zhao2, Lizheng Shi3, Jackie Lu2 and MaryHelen Tran2, 1Wake Forest University School of Medicine, Winston-Salem, NC, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3Tulane University, New Orleans, LA

    Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with substantial economic and comorbidity burdens. However, the burden among PsO patients comorbid with PsA has…
  • Abstract Number: 2527 • 2014 ACR/ARHP Annual Meeting

    The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts

    Amandine Tubery1, Cristel Castelli1, Florence Erny1, Françoise Barchechath-Flaisler1, Sabrina Dadoun2, Bruno Fautrel3 and Cecile Gaujoux Viala1, 1Nîmes University Hospital, Rheumatology Department, Nimes, France, 2Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, 3Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France

    Background/Purpose: The addition of  biological agents in treatment strategies in chronic inflammatory arthritides have improved the possibility of controlling disease activity and slowing the progression…
  • Abstract Number: 1543 • 2014 ACR/ARHP Annual Meeting

    Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD-Naive Patients: Results from a Phase 3, Randomized, Controlled Trial

    Alvin Wells1, Adewale O. Adebajo2, Jacob A. Aelion3, Paul Bird4, Alan Kivitz5, Frédéric Lioté6, Piercarlo Sarzi-Puttini7, ChiaChi Hu8, Randall M. Stevens8 and Christopher J. Edwards9, 1Rheumatology & Immunotherapy Center, Franklin, WI, 2University of Sheffield, Sheffield, United Kingdom, 3West Tennessee Research Institute, Jackson, TN, 4Combined Rheumatology Practice, Kogarah, Australia, 5Altoona Arthritis & Osteoporosis Center, Duncansville, PA, 6Hôpital Lariboisière & University Paris Diderot, Paris, France, 7Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, 8Celgene Corporation, Warren, NJ, 9University Hospital Southampton, Southampton, United Kingdom

    Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA). PALACE…
  • Abstract Number: 2423 • 2014 ACR/ARHP Annual Meeting

    Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration

    José M. Senabre-Gallego1, José Rosas-Gómez de Salazar1, Esteban Salas-Heredia1, Gregorio Santos-Soler1, Francisca Llinares-Tello2, Carlos Santos-Ramirez3, Mabel Sánchez-Barrioluengo4, Xavier Barber-Vallés5, Rafaela Ortega3, Ana Pons1, Catalina Cano1 and Maria Luisa Lorente-Betoret1, 1Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, 2Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, 3Rheumatology, Hospital Marina Salud, Denia, Spain, 4Ingenio (CSIC-UPV), Universitat Politècnica de València, Valencia, Spain, 5Center of Operations Research, University Miguel Hernández, Elche, Spain

    Background/Purpose To estimate the prevalence of subclinical synovitis detected by ultrasound in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients in clinical remission receiving anti-TNFα…
  • Abstract Number: 1550 • 2014 ACR/ARHP Annual Meeting

    Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting

    Proton Rahman1, Denis Choquette2, William Bensen3, Majed Khraishi4, Saeed Shaikh5, Regan Arendse6, Isabelle Fortin7, Andrew Chow8, Maqbool Sheriff9, Eliofotisti Psaradellis10, John S. Sampalis10, Susan Otawa11, Francois Nantel12, Allen J Lehman11 and May Shawi12, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, 3Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 4Nexus Clinical Research, St John's, NF, Canada, 5McMaster University, Hamilton, ON, Canada, 6University of Saskatchewan, Saskatoon, SK, Canada, 7Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, 8University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 9Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada

    Background/Purpose Spondyloarthritis, including psoriatic arthritis (PsA), is characterized by inflammatory arthritis affecting axial and peripheral joints. It is commonly associated with extra-articular and peri-articular manifestations…
  • Abstract Number: 2411 • 2014 ACR/ARHP Annual Meeting

    Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting

    John Kelsall1, Algis Jovaisas2, Proton Rahman3, Dalton Sholter4, Michael Starr5, William Bensen6, Maqbool Sheriff7, Wojciech Olszynski8, Michel Zummer9, Rafat Faraawi10, Andrew Chow11, Suneil Kapur12, Emmanouil Rampakakis13, John S. Sampalis13, Francois Nantel14, Susan Otawa15, May Shawi14 and Allen J Lehman15, 1The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 2194 Main Street, University of Ottawa, Ottawa, ON, Canada, 3Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 6St Josephs Hospital and McMaster University, Hamilton, ON, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8University of Saskatchewan, Saskatoon, SK, Canada, 9Université de Montréal, Montreal, QC, Canada, 10Medicine, McMaster University, Hamilton, ON, Canada, 11McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, 12Rheumatology, University of Ottawa, Ottawa, ON, Canada, 13JSS Medical Research, Montreal, QC, Canada, 14Janssen Inc., Toronto, ON, Canada, 15Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The…
  • Abstract Number: 1561 • 2014 ACR/ARHP Annual Meeting

    Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials

    Georg A. Schett1, Philip J. Mease2, Dafna D. Gladman3, Arthur Kavanaugh4, Adewale O. Adebajo5, Juan J. Gomez-Reino6, Jurgen Wollenhaupt7, Maurizio Cutolo8, Eric Lespessailles9, ChiaChi Hu10, Randall M. Stevens10, Christopher J. Edwards11 and Charles A. Birbara12, 1Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Swedish Medical Center and University of Washington, Seattle, WA, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4University of California San Diego, La Jolla, CA, 5University of Sheffield, Sheffield, United Kingdom, 6Rheumatology, Hospital Clinico Universitario, Santiago, Spain, 7Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 8Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, 9University of Orléans, Orléans, France, 10Celgene Corporation, Warren, NJ, 11University Hospital Southampton, Southampton, United Kingdom, 12University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps to regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…
  • Abstract Number: 2140 • 2014 ACR/ARHP Annual Meeting

    Agreement Among FDG-PET/CT, Ultrasound and Physical Examination in Patients with Inflammatory Arthritis

    Alexis Ogdie1, Shiv Sehra2, Viviane Khoury3, Yihui Jiang4, Shawn Rose5, Nehal N. Mehta6, Sally W. Pullman-Mooar7, Abass Alavi8, Joel Gelfand9 and Joshua Baker10, 1Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, 2Rheumatology, University of Pennsylvania, Philadelphia, PA, 3Department of Radiology, University of Pennsylvania, Philadelphia, PA, 4Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 6Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 7Rheumatology, University of Pennsylvania and Philadelphia Veterans Hospital, Philadelphia, PA, 8Department of Radiology/Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, 9Dermatology and Epidemiology, University of Pennsylvania., Philadelphia, PA, 10Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA

    Background/Purpose: The lack of tools to accurately measure and quantify joint inflammation is a challenging problem in the study of inflammatory arthritis. No gold standard…
  • Abstract Number: 1150 • 2014 ACR/ARHP Annual Meeting

    Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation

    Anna Cooper1, Johan A. Karlsson2 and Anders Gülfe1, 1Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, 2Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden

    Background/Purpose: Health related quality of life (HRQoL) can be expressed as utility, a value anchored at 0 (death) and 1 (perfect health, forming the basis…
  • Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting

    Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register

    Saedis Saevarsdottir1, Michele Santacatterina2, Leszek Stawiarz3, Carl Turesson4, Helena Forsblad5, Lennart T.H. Jacobsson6 and Staffan Lindblad7, 1Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 2Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 3Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 4Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 5Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 7Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
  • Abstract Number: 336 • 2013 ACR/ARHP Annual Meeting

    Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up

    Arane Thavaneswaran1, Vinod Chandran2 and Dafna D. Gladman2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Our previous research showed that baseline characteristics would enable the sub-categorization of psoriatic arthritis (PsA) into the distinct phenotypic groups of axial and peripheral…
  • Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting

    Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice

    Gabriela Ávila1, Sara Marsal1, Arnald Alonso1, Carolina Diaz2, Estefanía Quesada-Masachs2, María López-Lasanta1 and Isabel Acosta3, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, 3Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
  • Abstract Number: 339 • 2013 ACR/ARHP Annual Meeting

    The Association Between Obesity and Radiographic Progression Of Joint Damage Among Patients With Psoriatic Arthritis

    Lihi Eder1, Arane Thavaneswaran1, Vinod Chandran2, Richard J. Cook3 and Dafna D. Gladman2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada

    Background/Purpose: The prevalence of obesity among patients with psoriatic arthritis (PsA) is increased compared to the general population. Obese patients with PsA tend to respond…
  • Abstract Number: 1462 • 2013 ACR/ARHP Annual Meeting

    Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort

    Andra Negoescu1, Elena Nikiphorou2, Anshuman P. Malaviya3, Andrew Badcock3, John D. Fitzpatrick3,4, Calum T. Goudie3,4 and Andrew J. Ostor3, 1Rheumatology, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, 2Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, 3Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, 4University of Cambridge Medical School, Cambridge, United Kingdom

    Background/Purpose:   Due to its efficacy and perceived safety, methotrexate (MTX) has become the foundation disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA) however…
  • Abstract Number: 301 • 2013 ACR/ARHP Annual Meeting

    Arthritis and Nail Involvement In Patients With Plaque-Type Psoriasis

    Odirlei Andre Monticielo1, Karen Regina Rosso Schons2, Cristiane Faccin Knob2, Walter Neumaier2, Maristela de Oliveira Beck2 and André Avelino Costa Beber2, 1Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Universidade Federal de Santa Maria, Santa Maria, Brazil

    Background/Purpose: Psoriasis is a chronic disease that presents in individuals of all ages, affecting skin, nails and joints. Nail changes are estimated to be present…
  • « Previous Page
  • 1
  • …
  • 87
  • 88
  • 89
  • 90
  • 91
  • …
  • 93
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology